Healthcare Sector Taps AI Boom via Intuitive Surgical Stock (ISRG)

When investors think of artificial intelligence (AI), names like Nvidia (NVDA), Palantir (PLTR), and Alphabet (GOOGL) typically come to mind. But AI’s impact extends well beyond the traditional tech sector. A standout example is Intuitive Surgical (ISRG), the clear global leader in robotic surgery, now making significant strides in integrating AI into healthcare. The company’s latest system, the da Vinci 5, incorporates AI capabilities that could unlock a powerful new and recurring revenue stream.

Despite its leadership position, Intuitive Surgical’s stock remains more than 15% below its all-time high, primarily due to competitive concerns, which may offer a compelling entry point for long-term investors. Given Intuitive Surgical’s strong technological moat, I believe concerns about competition are overstated. The company’s sustained innovation and market leadership position it well to remain a long-term winner.

Thanks to the widespread adoption of its flagship da Vinci system, Intuitive Surgical commands an estimated 60% share of the global robotic surgery market in 2024. Once a system is installed, the company benefits from a steady stream of recurring revenue through the sale of consumables such as surgical instruments. Additionally, hospitals often choose to upgrade their systems over time to stay aligned with the latest technology, further reinforcing this revenue model.

In 2024, Intuitive Surgical generated $8.4 billion in revenue, marking a 17% year-over-year increase—a testament to its ability to effectively monetize its platform. But beyond the strong financials, the company’s intangible advantages significantly deepen its competitive moat. Over the past three decades, the da Vinci system has amassed an extensive base of real-world clinical data, contributing to better patient outcomes—something that is difficult, if not impossible, for competitors to replicate quickly.

Moreover, Intuitive Surgical is deeply embedded in healthcare systems worldwide. Hospitals invest heavily in training surgical teams, adapting clinical protocols, and integrating the technology into their workflows. This creates substantial switching costs and a high degree of operational lock-in. Even if a competitor were to offer a lower-cost alternative, the economic and logistical barriers to switching remain a significant deterrent.

Launched in early 2024, the da Vinci 5 introduces advanced AI capabilities that could further solidify Intuitive Surgical’s dominance in the robotic surgery market. This latest system marks a significant shift—from basic surgical automation to intelligent surgical augmentation. According to the company, the da Vinci 5 delivers 10,000 times the computing power of previous models, enabling it to process complex data in real-time and provide intelligent, context-aware support to surgeons during procedures.

This enhanced computing power allows the system to capture and analyze detailed intraoperative data, which can then be used to optimize surgical workflows, tool usage, and procedural techniques. Over time, this creates a powerful data-driven flywheel, continuously improving outcomes and efficiency in the operating room, deepening Intuitive Surgical’s competitive edge.

Admittedly, the competitive landscape in surgical robotics is becoming increasingly dynamic. Medtronic (MDT), a long-standing medtech leader, is preparing to launch its robotic-assisted surgery (RAS) system, Hugo, with FDA approval expected later this year. Hugo is positioned to compete in soft tissue procedures such as urology and gynecology, as well as spine surgery, and is expected to leverage AI as a key differentiator.

Meanwhile, Johnson & Johnson (JNJ) is advancing its Ottava system through clinical trials, targeting procedures like gastric bypass and hiatal hernia repair, directly competing with da Vinci in the minimally invasive space. Ottava features four robotic arms integrated into a standard surgical table, a design that aims to improve workflow efficiency by reducing equipment footprint in the operating room.

Additionally, Stryker’s Mako system continues to gain traction in orthopedic procedures, including hip, knee, spine, and shoulder surgeries. While Intuitive Surgical remains the clear leader in robotic-assisted soft tissue surgery, these emerging systems reflect a broader push by competitors to gain ground across various surgical specialties.

While Intuitive Surgical’s 60% market share may face some erosion as competition intensifies, the robotic surgery market is both vast and expanding, providing ample room for multiple players to thrive. Importantly, Intuitive Surgical’s first-mover advantage remains a significant asset, having established deep clinical integration and brand trust over the course of several decades.

Crucially, the company is consistently profitable and continues to invest heavily in research and development, reinforcing its ability to innovate and stay ahead of emerging competitors. These factors should help Intuitive Surgical sustain its leadership position even as the market evolves.

On Wall Street, ISRG earns a Strong Buy consensus rating based on 18 Buy, two Hold, and one Sell ratings in the past three months. ISRG’s average price target of $596.35 implies a 14.15% upside potential over the next twelve months.

Earlier this week, William Blair analyst Brandon Vazquez maintained a Buy rating on ISRG. He addressed concerns over the emergence of third-party remanufactured instruments, which could threaten the company’s highly profitable and recurring instruments and accessories segment.

The analyst “believes that the limited availability of FDA-cleared remanufactured instruments and the absence of third-party verification participation will likely restrict their widespread adoption. Vazquez also notes that hospitals may be hesitant to operate outside Intuitive Surgical’s ecosystem due to the high costs and risks associated with robotics programs.”

The launch of the da Vinci 5 marks Intuitive Surgical’s formal entry into the AI space, reinforcing its position at the forefront of the evolving robotic surgery market, even as competition intensifies.

That said, several risks extend beyond the competitive landscape. Despite its recent pullback, Intuitive Surgical remains richly valued, trading at a P/E ratio of 77.2, which is well above that of its industry peers, leaving limited margin for error. The company also faces external pressures, including tariffs (estimated to impact about 1.7% of revenue) and the complexities of global expansion.

Additionally, it is exposed to broader healthcare and regulatory shifts, such as the potential decline in bariatric surgery volumes resulting from the increasing use of GLP-1 medications. As AI becomes more central to its platform, data privacy concerns may also present regulatory and reputational challenges.

Ultimately, Intuitive Surgical’s strong market leadership and early integration of AI in a large, rapidly evolving industry give me confidence in the company’s long-term potential, despite the presence of near-term risks and challenges.

Disclaimer & DisclosureReport an Issue